Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
KD-025 by Nanjing KAEDI Biotech for Medulloblastoma: Likelihood of Approval
KD-025 is under clinical development by Nanjing KAEDI Biotech and currently in Phase I for Medulloblastoma. According to GlobalData, Phase...
KD-025 by Nanjing KAEDI Biotech for Glioblastoma Multiforme (GBM): Likelihood of Approval
KD-025 is under clinical development by Nanjing KAEDI Biotech and currently in Phase I for Glioblastoma Multiforme (GBM). According to...
KD-025 by Nanjing KAEDI Biotech for Solid Tumor: Likelihood of Approval
KD-025 is under clinical development by Nanjing KAEDI Biotech and currently in Phase I for Solid Tumor. According to GlobalData,...
KD-025 by Nanjing KAEDI Biotech for Hepatocellular Carcinoma: Likelihood of Approval
KD-025 is under clinical development by Nanjing KAEDI Biotech and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData,...